SSS. William Stavropoulos

S. William Stavropoulos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


S. William Stavropoulos has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Benjamin J. Shin

    Division of Interventional Radiology, Department of Radiology, Hospital of the University of Pennsylvania, Perelman School of Medicine, 1 Silverstein, 3400 Spruce Street, Philadelphia, PA 19104

    2 shared publications
  • Jeffrey Forris Beecham Chick

    Division of Interventional Radiology, Department of Radiology, Hospital of the University of Pennsylvania, Perelman School of Medicine, 1 Silverstein, 3400 Spruce Street, Philadelphia, PA 19104

    2 shared publications
  • Alvin C. Silva

    Department of Radiology, Mayo Clinic Hospital, Scottsdale, Arizona

    1 shared publication
  • Beiji Zou

    School of Informatics and Engineering, Central South University, Changsha, Hunan, China

    1 shared publication
  • Deepak Sudheendra

    Division of Interventional Radiology, Department of Radiology, Hospital of the University of Pennsylvania, Perelman School of Medicine, 1 Silverstein, 3400 Spruce Street, Philadelphia, PA 19104

    1 shared publication
  • Gregory J. Nadolski

    University of Pennsylvania

    1 shared publication

Latest Publications

  • Top Cited Papers

    Deep Learning to Distinguish Benign from Malignant Renal Lesions Based on Routine MR Imaging

    by Ianto Lin Xi, Yijun Zhao, Robin Wang, Marcello Chang, Subhanik Purkayastha, Ken Chang, Raymond Y. Huang, Alvin C. Silva, Martin Vallières, Peiman Habibollahi, et al.

    Purpose: With increasing incidence of renal mass, it is important to make a pretreatment differentiation between benign renal mass and malignant tumor. We aimed to develop a deep learning model that distinguishes benign renal tumors from renal cell carcinoma (RCC) by applying a residual convolutional neural network (ResNet) on routine MR imaging. Experimental Design: Preoperative MR images (T2-weighted and T1-postcontrast sequences) of 1,162 renal lesions definitely diagnosed on pathology or imaging in a multicenter cohort were divided into training, validation, and test sets (70:20:10 split). An ensemble model based on ResNet was built combining clinical variables and T1C and T2WI MR images using a bagging classifier to predict renal tumor pathology. Final model performance was compared with expert interpretation and the most optimized radiomics model. Results: Among the 1,162 renal lesions, 655 were malignant and 507 were benign. Compared with a baseline zero rule algorithm, the ensemble deep learning model had a statistically significant higher test accuracy (0.70 vs. 0.56, P = 0.004). Compared with all experts averaged, the ensemble deep learning model had higher test accuracy (0.70 vs. 0.60, P = 0.053), sensitivity (0.92 vs. 0.80, P = 0.017), and specificity (0.41 vs. 0.35, P = 0.450). Compared with the radiomics model, the ensemble deep learning model had higher test accuracy (0.70 vs. 0.62, P = 0.081), sensitivity (0.92 vs. 0.79, P = 0.012), and specificity (0.41 vs. 0.39, P = 0.770). Conclusions: Deep learning can noninvasively distinguish benign renal tumors from RCC using conventional MR imaging in a multi-institutional dataset with good accuracy, sensitivity, and specificity comparable with experts and radiomics.


  • A 16-F Sheath with Endobronchial Forceps Improves Reported Retrieval Success of Long-Dwelling “Closed Cell” Inferior Vena Cava Filter Designs

    by Jeffrey Forris Beecham Chick, S. William Stavropoulos, Benjamin J. Shin, Richard D. Shlansky-Goldberg, Jeffrey I. Mondschein, Deepak Sudheendra, Gregory J. Nadolski, Micah M. Watts, Scott O. Trerotola


  • Contemporary Status of Percutaneous Ablation for the Small Renal Mass

    by Benjamin J. Shin, Jeffrey Forris Beecham Chick, S. William Stavropoulos

    Renal cell carcinoma is the tenth most common malignancy in the USA, with upwards of 61,000 new cases and resulting in more than 14,000 deaths annually. Although partial nephrectomy remains the standard treatment, image-guided nephron-sparing ablative techniques including cryoablation, radiofrequency ablation, and microwave ablation have emerged as treatment options in certain patient populations. Ablative therapies have high technical successes, low tumor recurrence rates, and preserve renal parenchymal volume. The purpose of this article is to provide an update on ablation therapies for small renal masses.